Age-related macular degeneration causes irreversible vision loss in over twenty million patients in the US alone. Existing treatments slow progression, but have no impact on the upstream drivers of disease.

Ocutheia is pioneering a new approach to preserving vision by targeting metabolic dysfunction in photoreceptors. Our molecular target is upstream of clinically validated mechanisms of action, has a history of demonstrated clinical safety, and has broad therapeutic potential in the retina and even beyond the eye.